RxDoctor Payments Data

Alisa Kim, MD

Ophthalmology · Rockville, MDNPI 1114968336

Payments from drug & device makers

$1,517in general payments, 2019–2025

Across 21 payments — averaging $72.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$367
  • NEW World Medical,inc.$246
  • Shire North American Group Inc$244
  • AbbVie$209
  • Bausch & Lomb Americas Inc.$126
  • Aerie Pharmaceuticals, Inc.$116
  • plus $207 from 6 others

What the payments were for

  • Food & beverage$1,46296%
  • Education$181%
  • Gifts$372%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,517 in reported general payments places this provider in the 50th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$154,012
Medicare patients
340
Services billed
1,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine46$65,065
CequaCyclosporine24$23,636
LumiganBimatoprost15$11,931
CombiganBrimonidine Tartrate/Timolol20$9,858
ProlensaBromfenac Sodium15$5,748
Loteprednol Etabonate15$3,337
Bepotastine Besilate17$3,136
Prednisolone Acetate45$2,752
Bromfenac Sodium16$2,578
ErythromycinErythromycin Base86$889
Doxycycline Hyclate11$817
Timolol Maleate49$766
Latanoprost57$671
Brimonidine Tartrate25$636
MoxifloxacinMoxifloxacin Hcl24$566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$209$86,85381 claims
Sun Pharmaceutical Industries Inc.Cequa$367$23,63624 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$100$9,08530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →